Updated Terms of Use & Privacy Policy

We’ve updated our Terms of Use, and Privacy Policy. Please take a moment to review the changes.

MET as a NSCLC Target

Episode
135
Soundcloud
Share

This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
D. Ross Camidge, MD, PhD
D. Ross Camidge

MD, PhD

Director of Thoracic Oncology
University of Colorado Cancer Center
Noemí Reguart
Noemí Reguart

MD, PhD

Associate Professor and Director of the Thoracic Oncology Unit
Hospital Clinic of Barcelona
University of Barcelona's School of Medicine